Cat. No.: X23-10-ZQ375
JAK inhibitor Filgotinib, Purity ≥98%
Synonym: 1206101-20-3; Filgotinib; GLPG0634; 1206161-97-8; N-(5-(4-((1,1-Dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide; JAK inhibitor
- MDL: MFCD20527867
- CAS Number: 1206161-97-8
- Compound CID: 49831257
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Properties
Description
Filgotinib, soluble in DMSO and insoluble in ethanol and water, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, and TYK2.
Molecular Formula
C21H23N5O3S
Targets
JAK1: 10 nM; JAK2: 28 nM; JAK3: 810 nM; TYK2: 116 nM
Solubility
DMSO: 75 mg/mL (176.26 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
Filgotinib is used to investigate the inhibition of JAK1 in the treatment of inflammatory bowel diseases and rheumatoid arthritis.
Related Products
-
JAK inhibitor JAK/HDAC-IN-1, Purity ≥98%
-
JAK inhibitor 1,2,3,4,5,6-Hexabromocyclohexane, Purity ≥98%
-
JAK inhibitor Abrocitinib, Purity ≥98%
-
JAK inhibitor AZ-3, Purity ≥98%
-
JAK inhibitor AZ-960, Purity ≥98%
-
JAK inhibitor AZD1480, Purity ≥98%
Quick Links